Objectives: It is important for consumers, clinicians and health service planners to know the risk of recurrence of primary breast cancer after initial treatment. At present, none of Australia's state or territory cancer registries routinely report this information. We aimed to determine the incidence of recurrence in New South Wales (NSW) clinical practice for the period 18 months to 6 years after diagnosis of primary breast cancer.
Introduction
Outcomes for the majority of women diagnosed with primary breast cancer are good, with 5-year survival more than 80%.
1 However, some women will progress to more advanced disease and ultimately die of their cancer. Active treatment for primary breast cancer typically involves surgical removal of a tumour and a course of radiotherapy and/or chemotherapy 2 , all of which would normally be completed within 18 months of diagnosis. Recurrence refers to the return of cancer after active treatment and a cancer-free period.
3 Breast cancer may return to the same or the other breast (local recurrence), chest wall or lymph nodes (regionalised recurrence), or elsewhere in the body (distant metastasis).
2 When detected, recurrence may be treated with surgery, radiotherapy, chemotherapy and pharmacotherapy. 2 The risk of recurrence is known to be higher for women with node-positive 4 , human epidermal growth factor receptor 2 (HER2)-positive 5 and hormone receptornegative 6 tumours, and with increasing tumour size. 7 Understandably, recurrence is of utmost concern for women diagnosed with primary cancer. 8 Timely and accurate data on the incidence of recurrence are also of high importance to clinicians and health service planners, and could assist in treatment decision making and assessment of treatment outcomes. 9−11 To date, none of Australia's state or territory cancer registries routinely collect or report statistics on recurrence.
12− 19 The New South Wales (NSW) Cancer Registry collects information on 'new episodes of active treatment' in hospitals 13 for individuals with previously reported tumours, and this has been used as a proxy measure of breast cancer recurrence. 9 However, these data are not available to researchers 12 and exclude women treated outside the hospital system (i.e. those receiving pharmacotherapy or radiotherapy only, administered on an outpatient basis in NSW). In addition, few state or territory registries collect information on clinical factors that are likely to affect recurrence, such as HER2 and hormone receptor status, and the type of initial treatment received (e.g. chemotherapy, surgery).
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To date, only one research group has obtained data on new episodes of treatment from the NSW Cancer Registry 9 , which were used to estimate rates of progression to distant metastasis (metastatic breast cancer). Lord and colleagues 9 estimated the 5-year cumulative incidence of metastatic cancer among 6644 women diagnosed with primary breast cancer in NSW in 2001−2002. Women without a NSW hospital admission between 2001 and 2007 were excluded from the study, and follow-up was not censored for metastasis or death (i.e. person-time at risk was not calculated). The impact of tumour size, HER2 status, hormone receptor status and initial treatment could not be examined with available data. The authors reported an overall 5-year cumulative incidence of 10% (2% per year). Their study currently provides the only Australian population-based data for breast cancer recurrence and is one of the few international studies to estimate recurrence outside of clinical trials. 9 However, it is likely to underestimate the true incidence of breast cancer recurrence because local and regionalised recurrences were not captured, and women not receiving hospital treatment were excluded. 9 Australia has several linkable, whole-population administrative health datasets available to researchers that can potentially be used to estimate breast cancer recurrence rates, and which contain information about tumour characteristics and initial therapy that is not routinely collected by registries. For example, Pharmaceutical Benefits Scheme (PBS) claims can be used to determine whether women have been dispensed trastuzumab for primary HER2-positive tumours, endocrine therapy for hormone receptor-positive tumours, or a therapy restricted for use in those with advanced breast cancer.
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This study aimed to determine population-based estimates of recurrence in the period following completion of active treatment for primary breast cancer (18 months to 6 years postdiagnosis).
Methods

Study population
The cohort was selected from women enrolled in the Sax Institute's 45 and Up Study, a cohort of approximately 267 000 adults (143 014 women) aged ≥45 years residing in NSW, Australia. 21 Participants joined the study between January 2006 and December 2009. 22, 23 Although the cohort was derived from the general population, the modest response fraction (18%) means that it is not likely to represent the NSW population.
21,24 Information regarding the establishment and recruitment of the cohort is described elsewhere. 
Data sources and linkage
We accessed unit-record, linked data from i) the 45 and Up Study baseline survey, ii) the NSW Cancer Registry, iii) the NSW Admitted Patient Data Collection (all admissions to public and private hospitals), iv) PBS claims (all subsidised medicines), v) Medicare Benefits Schedule (MBS) claims (all subsidised outpatient consultations and investigations), and vi) the NSW Registry of Births, Deaths and Marriages (all deaths in NSW) ( Table 1) . PBS and MBS data were supplied by the Australian Government Department of Human Services and deterministically linked to the 45 and Up Study baseline data. The remaining datasets were probabilistically linked by the NSW Centre for Health Record Linkage
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, with quality audits showing fewer than 0.5% false positive links. 26 
Ethics
Participants were drawn from the 45 and Up Study cohort. All cohort members provided written consent to join the 45 and Up Study, to have their routinely collected health data linked, and for these data to be provided to thirdparty researchers for approved projects. This consent procedure was approved by the University of New South Wales Human Research Ethics Committee and the Australian Government Department of Health. The current study also received approval from the University of Western Australia Human Research Ethics Committee (approval RA/4/1/4589), and the NSW Population and Health Services Research Ethics Committee (approval HREC/11/CIPHS/35).
Ascertaining incidence of breast cancer recurrence
We ascertained recurrence from i) specified surgeries, chemotherapy or radiotherapy occurring for the first time 18 months or more after the date of diagnosis, or at least 12 months after previous claims for either surgery, chemotherapy or radiotherapy (indicating a new round of treatment); or ii) first dispensing of a medicine indicated only for 'advanced' or 'metastatic' breast cancer during the study period 20 ( Table 2 ). The time between 18 months postdiagnosis and end of follow-up (or censoring date) was used to calculate person-time at risk for each participant.
Demographic, clinical and initial treatment characteristics
To optimise comparability with previously reported data from an Australian setting, we examined demographic and clinical subgroups using the same categories as Lord and colleagues. 9 Women's age (<50, 50-69, ≥70 years), node status (positive 'localised tumours', negative 'regionalised tumours'), morphology (invasive ductal, lobular, other), tumour size (>2 cm, ≤2 cm or unknown), area of residence (major city, other) and social disadvantage at diagnosis (least, middle, most) were obtained from the NSW Cancer Registry. Country of birth was reported by participants in the 45 and Up Study baseline survey (Australia or New Zealand, other). The initial treatment characteristics examined within 18 months of diagnosis were i) dispensing of trastuzumab (a proxy for HER2-positive status), ii) dispensing of endocrine therapy (a proxy for hormone receptor-positive status), iii) initial surgery type, and iv) chemotherapy. PBS data were used to determine whether participants had been dispensed trastuzumab (4632T, 4639E) or a first-line endocrine therapy (anastrozole 8179L; letrozole 8245Y; tamoxifen 2109B, 2110C) within 18 months of diagnosis. PBS supply of trastuzumab is restricted to women with primary HER2-positive tumours; and anastrozole, letrozole and tamoxifen are restricted to women with hormonedependent tumours. 20, 27 Hospital claims were used to identify the first breast cancer surgery women underwent within 18 months of diagnosis (lumpectomy, mastectomy, none; Table 2 ). MBS and hospital records were used to identify whether chemotherapy was administered within 18 months of diagnosis.
Statistical analysis
The number and proportion of all participants with different baseline characteristics were calculated. Annual incidence rates were calculated by dividing the number of incident cases of recurrence by the total person-years at risk. Annual incidence was calculated for all women, and by baseline and initial treatment characteristics. Kaplan-Meier curves were used to determine the time from end of active treatment and recurrence, stratified by node status at diagnosis. Univariate Cox proportional hazards regression analysis was used to determine the rate of recurrence for women with different baseline and initial treatment characteristics. Within each characteristic examined, the group with the lowest annual incidence was used as the referent. Multivariate Cox modelling was also conducted to determine which characteristics independently predicted recurrence. For each variable in the Cox models, the proportional hazards assumption was tested visually using Kaplan-Meier curves and by examining a plot of -log(-log(survival time)) against time. For comparability with previous Australian research 9 , we initially included all variables in the multivariate model and used backward stepwise elimination to derive the final most parsimonious model. Hazard ratios (HRs) and 95% confidence intervals (95% CI) were calculated for each characteristic. All analyses were conducted using SPSS version 19.
Results
Time to recurrence
Of the 2416 women diagnosed with primary invasive breast cancer, 217 (9%) had a hospital, MBS or PBS claim indicating recurrence during the study period. From 18 to 30 months postdiagnosis, the cumulative incidence of recurrence for all women was 4%, rising to 11.9% by 66 months (Figure 1 ). When stratifying time to recurrence by node status, it was apparent that women with nodepositive tumours had substantially higher cumulative incidence of recurrence at each time point than women with node-negative tumours.
Unadjusted regression analyses
Women with node-positive tumours at diagnosis had significantly higher annual recurrence rates than women who had node-negative tumours (4.8% vs 2.5%, p < 0.001; Table 3 ). Recurrence rates were also higher for women with tumours >2 cm at diagnosis compared with other women (4.8% vs 2.7% per year, p < 0.001). Women who initially had chemotherapy had higher rates of recurrence than women who did not (4.4% vs 3.0% per year, p = 0.015), as did women undergoing mastectomy compared with lumpectomy (4.6% vs 3.0% per year, p = 0.019). There was no significant difference in recurrence between women with hormone receptornegative tumours and those with receptor-positive tumours (3.8% vs 3.1% per year; p = 0.151). HER2 status was not significantly associated with differences in recurrence rates. We did not find any difference in recurrence rates based on women's age, tumour morphology, area of residence, social disadvantage or birth country. 
Adjusted regression analyses
Multivariate Cox regression analysis, which initially included all variables from the univariate modelling, resulted in a final model showing that women with node-positive tumours were 73% more likely to develop recurrent cancer than those diagnosed with nodenegative tumours (HR = 1.7; 95% CI 1.3, 2.3; Table 3 ). Women with tumours >2 cm at baseline had a 52% higher chance of recurrence than other women (HR = 1.5; 95% CI 1.1, 2.0). Hormone receptor status predicted recurrence risk after adjusting for other variables, with recurrence 33% more likely for women with receptornegative tumours (HR = 1.3; 95% CI 1.0, 1.7). No other variables, including initial chemotherapy or initial surgery, had a significant effect on incidence of recurrence in the multivariate model.
Discussion
Using multiple routinely collected health datasets, we found that NSW women diagnosed with primary breast cancer developed recurrent breast cancer at a rate of 3.3% per year in the period between 18 months and 6 years postdiagnosis. This is considerably higher than the metastatic breast cancer incidence that Lord and colleagues identified from NSW Cancer Registry data 9 (2.0% per year). In keeping with previous Australian data
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, we found that recurrence was independently predicted by node status, but did not find a relationship with age or social disadvantage. Our finding that recurrence risk is greater for women with node-positive or hormone receptor-negative tumours after adjustment for other variables is consistent with existing international evidence.
4−6 Recurrence estimates are likely higher in our study than previously reported by Lord and colleagues because of our capture of local and regionalised recurrences in addition to distant metastases. We also captured recurrence treated outside of hospitals, and did not begin following women until 18 months postdiagnosis, when active treatment was complete.
We did not find higher risk of recurrence for women with HER2-positive tumours, despite clinical trial evidence that this is a strong predictor of recurrence. 28 It is likely that we underascertained women with HER2-positive tumours, because only 5% of our cohort was dispensed trastuzumab, and approximately 25% of women diagnosed with breast cancer are reported to have HER2-positive tumours. 29 Trastuzumab was not PBS-listed for primary HER2-positive tumours until October 2006 and was therefore unavailable to the women in our study who completed active treatment earlier (62% of our sample), possibly explaining this finding. 27 
Strengths and weaknesses
To our knowledge, this is the first study to determine recurrence incidence rates, rather than cumulative incidence, in the years following active treatment for primary breast cancer in Australian clinical practice. This is also the first study to examine the influence of initial treatment on rates of recurrence in Australian practice. A further novel aspect of this study is ascertainment of recurrence using datasets and variables that are widely available to researchers, allowing ongoing monitoring of recurrence rates over time in the absence of routinely collected or available recurrence data from Australia's cancer registries. We used health records for a heterogeneous community sample for which all hospital admissions and publicly subsidised medicines and outpatient services had been captured.
There are limitations to this study. We were not able to directly assess breast cancer recurrence because of the unavailability of such data, and had to combine records from multiple datasets on surgeries, medicines and services used to treat recurrence. Our group has previously used this method to determine recurrence 30 , as have a number of studies in the US.
10, 31 A US study was able to assess the validity of this method against chart review, and reported sensitivity and specificity of 92% and 94%, respectively. 31 We could not differentiate between local and regionalised recurrence and distant metastasis, and did not have access to the relevant NSW Cancer Registry data to validate metastatic cases. We were also unable to differentiate between new primary tumours and recurrences occurring after the end of NSW Cancer Registry data in December 2008. Finally, we were not able to ascertain surgeries or inpatient radiotherapy and chemotherapy administered outside NSW (for women who sought treatment in another state). Despite these limitations, our overall results and patterns observed in Figure 1 . Kaplan-Meier curve showing time to breast cancer recurrence for all women and by node status at diagnosis participant subgroups are similar to (but higher than) those reported previously from this source. Our sample was drawn from the 45 and Up Study, limiting the cohort to individuals aged ≥45 years at the time of recruitment to the study. The study had a relatively modest response fraction; however, direct representativeness is not required to demonstrate valid relationships between exposures and outcomes 32 , and previous work has demonstrated that internal comparisons from this cohort are valid and reliable.
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Although primary breast cancer is usually diagnosed in women in their sixties 33 , young women, who are more likely to have aggressive cancers, are under-represented in our study. 34 We could not directly ascertain whether women in our cohort had HER2-positive or hormone receptor-positive tumours; however, trastuzumab and the endocrine therapies were only PBS-subsidised for women with these respective characteristics during the study period. 
Conclusion
Our results indicate that women with primary breast cancer in NSW practice develop recurrent breast cancer at the rate of 3.3% annually in the period 18 months to 6 years after diagnosis -substantially higher than the 2.0% annually reported previously. 9 In a 2007 Australian survey, consumers reported 'up-to-date information' and 'managing concerns about cancer coming back' as among their greatest unmet needs 8 , highlighting the need for timely and accurate recurrence data from Australian practice. The method we report for ascertaining breast cancer recurrence can be used to assess populationlevel changes over time and to investigate the real-world impact of specific treatments on outcomes in the absence of available Cancer Registry data on recurrence.
